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1. Introduction  
The introduction of genes into the organism or the regulation of the expression of 
endogenous genes has emerged in the last decade as a very potent strategy for correcting 
monogenic inherited diseases, treating acute disorders, and slowing down the progression 
of diseases without known cure. In addition it constitutes an important tool for research, 
which has been widely used and has contributed to show the mechanisms behind several 
physiological processes and pathologies. 
Adequate carriers able to transfer DNA or RNA into target cells have been largely explored. 
However, this is an area under continuous expansion as there is no ideal vector suitable for 
all applications. In fact, no individual vector will meet all the characteristics for a perfect or 
ideal vector, as many of the needs are different and even contradictory. For example, 
immunogenicity is in most cases an undesirable side effect, while it is a valuable property 
when treating tumours as it contributes to their clearance. Another example of contradictory 
needs of one single vector would be the capacity of a vector to determine the overexpression 
of the transgenic protein for life. This would be an essential property for the treatment of 
inherited diseases produced by the lack of a particular protein, however for the treatment of 
acute injuries the lifelong expression of a therapeutic protein will probably be deleterious. 
Moreover, some vectors do not transduce post-mitotic cells like neurons or muscle fibres, 
which is a drawback for targeting these cell types but may be an advantage for the targeting 
of cancer cells. Thus, there is a need for diverse type of vectors for diverse therapeutic or 
experimental paradigms, and in particular versatile tuneable vectors would be very 
interesting. Moreover, several basic problems with the known vectors persist, like toxicity, 
oncogenicity, immunogenicity, low transfection efficiency, or poor bioavailability, which 
need further consideration and efforts.  
Due to their natural efficiency, viruses have been modified to act as vectors, and they have 
shown a good degree of success. Non-viral vectors have also been developed by combining 
several properties necessary for transfection: nucleic acid attachment and condensation, cell 
attachment, cell entry, endosomal escape, intracellular trafficking, nuclear entry, and nucleic 
acid release. Some of these vectors are quite simple, as the ones formed by the combination 
of nucleic acids and lipid components or other carriers like polyethylene glycol (PEG). 
Others include the previous components but have in addition attached targeting molecules 
like antibodies, enabling these vectors to preferentially transfect a given tissue. In fact even 
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magnetic fields have been used to concentrate suitable engineered vectors to a given area 
(Corchero and Villaverde 2009).  
An interesting type of non-viral vectors is the one based on multifunctional proteins (Aris 
and Villaverde 2004; Mastrobattista et al. 2006). The combination of functional domains in a 
single polypeptide is a simple yet powerful approach for the development of vectors 
suitable for gene therapy. In fact, this approach has generated the first prototypes of 
modular protein gene therapy vectors. Three general methods have been used for the 
engineering of these molecules: i) production of a recombinant protein by the direct fusion 
of the functional domains; ii) production of a recombinant protein by combining a known 
scaffold protein and several functional domains inserted into exposed regions of the scaffold 
protein; and iii) chemical conjugation of functional domains and proteins. Many of these 
vectors can be produced recombinantly, generating reproducible and stable stocks 
appropriate for the formulation of clinically usable drugs. Moreover, the modular nature of 
these versatile vectors enables the combination of different domains to fulfil the changing 
requirements of pathological end experimental situations. 
2. Functional domains available 
2.1 Nucleic acid attachment and condensation 
Trans-membrane transport of DNA is an inefficient process, and thus the successful 
introduction of a transgene into a target cell must include two important steps regarding the 
plasmid or oligonucleotid DNA that is included in the vector. First, the extended DNA 
needs to be condensed into an ordered compact nano-particle, and second, once inside the 
nucleus, the DNA must be de-condensed and thus accessible to transcription. Basic peptides 
or polycations have been exploited for the interaction with the DNA backbone due to their 
electrostatic interactions (Bloomfield 1996; Saccardo et al. 2009)(see Table 1). When DNA is 
mixed with these condensing agents, smaller molecules of different shapes are formed 
mainly depending on DNA size (Vijayanathan et al. 2002). For instance, in the absence of 
DNA, the HNRK modular vector that uses poly-lysine for DNA condensation, self-organize 
as amorphous, polydisperse particulate entities ranging from a few nanometres up to 
around one micron. However, in the presence of DNA, protein-DNA complexes appear as 
tight and rather monodisperse spherical-like nanoparticles of around 80 nm in diameter 
(Domingo-Espín et al. 2011). The most widely used condensing agent is a poly-lysine chain 
(Saccardo et al. 2009). Poly-lysine polymers containing at least 6 lysines will efficiently 
condense DNA, however, additional 4 to 9 lysines are needed to fully condensate the DNA 
into smaller particles of 50-100nm, increasing in this way many folds the transfection 
capacity (Wadhwa et al. 1997). Other basic peptides used are the poly-arginine peptides, 
which not only induce DNA condensation, but also show membrane translocation potential 
(Futaki et al. 2001) and nuclear translocation capacity, determining in this way transgene 
expression (Kim et al. 2003; Vazquez et al.).  
The condensed DNA by these peptides is partially protected from cellular acid nucleases of 
the lysosomal compartment (Krishnamoorthy et al. 2003; Ross et al. 1998; Wolfert and 
Seymour 1998) and serum nucleases, inducing an extended half-life in serum (Kumar et al. 
2007) and in the circulation, making tissue targeting possible (Kawabata et al. 1995; 
Nishikawa et al. 2000a). For example, the addition of the acid nuclease inhibitor DMI-2 
induced a 10-fold increase in receptor-mediated transfection in cultured cells exposed to a 
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Surfactant Protein A-poly-lysine modular vector or a transferrin-poly-lysine modular vector 
(Ross et al. 1998). Naturally DNA condensing proteins have also been used for the 
construction of modular vectors. For instance, Histones condense plasmid DNA and 
protects it from endonucleases, being the lysine-rich H1 Histone the most effective one 
(Pyhtila et al. 1976). Moreover, some nuclear localization signals like the NLS peptide from 
SV40 virus large T-antigen are lysine-rich peptides that when used as a tetramer can 
efficiently condense DNA without loosing its nuclear localization properties (Ritter et  
al. 2003).   
2.2 Cell attachment and cell targeting 
When a viral or non-viral gene therapy vector is injected intravenously, most of the vectors 
will localize mainly in the liver but also in the kidneys, lungs and spleen. While this is 
normally a problem to circumvent for most gene therapy applications, it constitutes an 
advantage for the expression of molecules in the liver. There are many fetal metabolic 
diseases resulting from a defect or a deciency of hepatocyte-derived proteins. Moreover, 
the liver can be considered as a platform to produce various proteins secreted into the 
blood. Therefore, many pioneer studies focused on the development of more efficient gene 
delivery systems for the introduction of therapeutic genes selectively into hepatocytes (Wu 
and Wu 1988). Intravenously injected plasmids are cleared from the circulation by the liver 
non-parenchymal cells by a scavenging receptor mediated mechanism (Kawabata et al. 
1995). When Nishikawa and colleagues administered naked 32PDNA into the tail vein of 
mice, about 40% and 10% of the radioactivity rapidly accumulated in the liver and kidneys, 
respectively (Nishikawa et al. 2000b). Again, the main cell-types targeted were the liver non-
parenchymal cells: Kupffer cells and endothelial cells. When they injected a vector 
composed of 32PDNA/polyornithine, little effect on the distribution of the DNA was 
observed. However, the injection of the 32PDNA/Gal-pOrn galactose-mediated hepatocyte-
targeting vector induced a 60% hepatic accumulation of radioactivity, but more 
interestingly, most of the targeted cells were now hepatocytes instead of Kupffer or 
endothelial cells. The same effect was observed at the level of luciferase transgene 
expression, indicating that the DNA/Gal-pOrn vector was not only able to adhere and enter 
preferentially into hepatocytes, but it could also transfect them. 
Many different domains of known proteins and sugars have been used for cell targeting of 
modular vectors, like galactose (Wu and Wu 1987), transferrin (Wagner et al. 1990), foot-and-
mouth disease virus integrin interacting peptide (Aris et al. 2000; Aris and Villaverde 2003; 
Domingo-Espín et al. 2011), nerve growth factor (Ma et al. 2004; Zeng et al. 2004), surfactant 
protein A (Ross et al. 1995), rabies virus glycoprotein (Kumar et al. 2007), tetanus toxin 
fragment Hc (Box et al. 2003; Knight et al. 1999), cholera toxin b chain (Barrett et al. 2004), and 
neurotensin (Navarro-Quiroga et al. 2002). In an interesting study, Arango-Rodríguez and 
colleagues showed that they could target only substantia nigra neurotensin high affinity 
receptor positive neurons by means of a modular vector that displayed neurotensin, while 
no other neurons were transfected (Arango-Rodriguez et al. 2006). In vivo, many of these 
targeting systems have shown success (see Table 1). An additional interesting targeting 
strategy is the use of antibodies (Berhanu and Rush 2008; Buschle et al. 1995; Thurnher et al. 
1994).  For instance, the use of the 1E3 antibody against the Tn antigen expressed on many 
carcinomas coupled to polylysine induced an important increase in the transfection of a 
cancer cell line (Thurnher et al. 1994). Another vector, named fkAbp75-ipr, possess several  
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functional domains (see Table 1), being one of them the monoclonal antibody MC192 against 
p75NTR, the low affinity neurotrophin receptor (Berhanu and Rush 2008). By injecting it 
intracerebroventricularly coupled to siRNA against TrkA, one of the high affinity 
neurotrophin receptors, Berhanu and Rush were able to down-regulate TrkA expression  
in p75NTR expressing cells and correlate this with functional alterations like impaired spatial 
memory.  
2.3 Endosomal escape 
A limiting step for receptor-mediated gene delivery is the escape from endosomes, as the 
vector needs to gain access to the cytosol to enter the nuclei. Fusogenic peptides are 
reported to strongly enhance in vitro gene transfer after being incorporated into carrier 
systems by chemical linkage (Box et al. 2003; Fisher and Wilson 1997; Navarro-Quiroga et al. 
2002; Nishikawa et al. 2000b; Ogris et al. 2001; Wagner et al. 1992) or by ionic interaction 
(Gottschalk et al. 1996; Plank et al. 1994), but co-treatment of the cells with the vector and the 
fusogenic peptide may also be effective (Read et al. 2005). The most widely used method for 
endosome escape is based on the amino-terminal motif of inuenza virus hemagglutinin 
subunit HA2 (Plank et al. 1994; Wagner et al. 1992). For example, Nishikawa and colleagues 
showed that when an acid-sensitive fusogenic peptide derived from HA2 was incubated 
with mouse erythrocytes at pH 5.0, it induced hemolysis while it did not show any 
signicant hemolytic activity at pH 7.4 (Nishikawa et al. 2000b). Interestingly, the same 
study showed that the in vivo liver transgene expression obtained after intravenous injection 
of the vector DNA/Gal-pOrn-mHA2 was 300 fold higher than that obtained with the same 
vector lacking the HA2 domain (Nishikawa et al. 2000b).  
Other domains used for DNA condensation or vector purification as polylysine or 
polyhistidine have shown endosome disrupting activities (Read et al. 2005; Zauner et al. 
1997). The most effective ones were histidine rich polyplexes formed by the condensation of 
approximately 50 monomers of Cys-His6-Lys3-His6-Cys and DNA (Read et al. 2005). In this 
study, the endosomolytic agent chloroquine, which normally enhance the transfection 
capacity of most non-viral vectors, did not enhance the transfection with the histidine rich 
polyplexes while it enhanced transfection with other non-viral vectors, suggesting that the 
poly-his domains are in fact endosomolytic. Though polycations like polylysine may be 
toxic to cells, especially if they have membrane-disrupting activity, this polyhistidine vector 
showed no toxicity. Histidine becomes positively charged when the pH decrease to less than 
7 and thus becomes useful for the permeabilization of the endosomal membrane induced by 
acidification of endosomes, increasing cell transfection (Midoux et al. 1998). In vivo, many of 
these endosomal escape systems have shown success (see Table 1). For an extensive review 
on different strategies and domains used for endosomal escape please refer to Ferrer-
Miralles et al. (Ferrer-Miralles et al. 2008). 
For the introduction of siRNA and DNA into cells, several cationic peptide transduction 
domains or also called cell-penetrating domains have been used. TAT, 8xArg, Hph-1or Antp 
domains can deliver a wide variety of cargo into primary cells, to most tissues, and are in 
addition being evaluated in clinical trials (Gump and Dowdy 2007). For instance, when the 
Tat-domain was combined with a poly-His domain and the (ds)RNA-binding domain 
DRBD, the vector coupled to siRNA could successfully down-regulate Luciferase expression 
in the nasal and tracheal passages for 4 days after intranasal administration (Eguchi et al. 
2009). An important characteristic of these systems using cell-penetrating peptides is that 
they are not cell-specific, and thus should be used for general non-selective transfection. A 
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careful evaluation of the toxicity of this cell penetrating domains in in vivo settings has to be 
performed as toxicity of Tat protein has been reported (Cardozo et al. 2007), specially for the 
CNS (Bonavia et al. 2001; Nath et al. 1996). In addition, toxicity of the Antp domain has also 
been reported for many cell types (Cardozo et al. 2007). 
2.4 Nuclear translocation 
The transgene expression levels obtained after plasmid DNA injection into the cytoplasm or 
the nucleus showed that de nuclear double membrane and its pores are important barriers 
for naked DNA (Liu et al. 2003; Pollard et al. 1998). The selection of macromolecules that will 
be actively imported into the nucleus occurs at the nuclear pore complex, which is 
composed of more than 50 different proteins. The pore complex will recognise importin 
proteins bound to short (normally 4-8 amino acids) nuclear localization signals which can be 
located almost anywhere in the amino acid sequence of the protein, and which are rich in 
the positively charged amino acids lysine and arginine and usually contains proline (Pouton 
1998). This mechanism has been exploited for the design of modular protein vectors, 
introducing nuclear localization sequences like the SV40 NLS peptide from the T antigen 
(Aris and Villaverde 2003; Fritz et al. 1996). For instance, Aris and co-workers introduced 
this nuclear localization sequence into the 249AL modular vector (see Table 1) and they 
observed an enhanced transgene expression with the resulting vector termed NLSCt (Aris 
and Villaverde 2003). However, studies performed in cells in culture show that even in the 
presence of nuclear localizations sequences, complexes of more than 60nm seem to be 
excluded (Chan et al. 2000). This data are in contrast to the high transfection efficiency 
obtained, even in vivo, with different modular protein vectors that exceeds this size, 
reaching 200nm (see Table 1). One can speculate that in fact some molecules of up to 
200nm can be imported into the nucleus by being flexible, or that during the interaction of 
the vector with the nuclear import machinery the vector is disassembled and only the 
DNA is imported. 
Another important step for efficient transgene expression may be the release of the nucleic 
acid from the vector once in the nucleus. Several studies have addressed the possible 
enhancement of the release of the DNA by the cellular reducing conditions. For example, 
histidine rich polyplexes were able to release the complexed DNA when exposed to the 
reducing agent Dithiothreitol (DTT), suggesting that in cells a similar mechanism would 
occur (Read et al. 2005). In fact, the increase in the cellular antioxidant and reducing agent 
glutathione, induced an important 200 fold increase in the transfection observed with the 
histidine rich polyplexes, but only a 3fold increase was observed with the PEI/DNA vector, 
another non-viral vector with no reduction-dependent release of DNA. Though this is an 
interesting phenomenon, it is difficult to understand why the cytosol reducing conditions do 
not disassemble the vector too early, determining that the DNA is released into the cytosol 
instead of inside the nucleus, not favouring the transfection process. 
2.5 Trophic vectors/functional vectors 
An attractive possibility is the combination of the effects mediated by the overexpression of 
a transgene and the direct effects of the vector per se. In fact, as modular vectors normally 
take advantage of a cell attaching motif for receptor mediated endocytosis, they tend to 
display intrinsic activities. More importantly, the use of trophic factors or toxin domains for 
cell attachment and internalization is ideal, as their natural mechanism of action includes 
the attachment to high affinity cell surface receptors, the endocytosis to early endosomes, 
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and even being transported to the cell soma in the case of neurons (Lalli and Schiavo 2002). 
An interesting modular vector was produced combining a polylysine tail with the loop 4 of 
the nerve growth factor (NGF) (Zeng et al. 2004; Zeng and Wang 2005). This “trophic vector” 
maintained the trophic effects of NGF, was able to condensate DNA, and when combined 
with polyethylenimine (PEI600), transfected cells in culture that expressed NGF receptors 
but not cells without these receptors. Interestingly, the DNA-PEI600 showed a size of 445nm 
and an zeta potential of 6,2mV, but the addition of the NGF loop4 poly-lysine peptide to the 
complex induced the formation of smaller 180nm particles with a zeta potential of 23,2mV 
(Zeng et al. 2007). This shows that the addition of targeting peptides to non-specific 
DNA/condensing products complexes may in fact contribute to enhance not only the 
targeted delivery but also to decrease the particle size and charge of the resulting vector. A 
somehow more complex trophic vector including NGF loops was also produced. It 
combined the loops 1 and 2 of NGF and the SPKR4 domain derived from histone H1 DNA 
binding motif, linked together by a A-helical linker (Ma et al. 2004). Both NGF-loop derived 
vectors could even transfer a transgene in vivo preferentially to dorsal root ganglia neurons 
(which express NGF receptors) after intrathecal spinal cord injection (Ma et al. 2004; Zeng et 
al. 2007). Several toxins have been used as cell attachment motifs (Andreu et al. 2008; Box et 
al. 2003; Knight et al. 1999), and some motifs of these toxins can in fact display trophic effects 
(Chaib-Oukadour et al. 2004), and have thus been used to design trophic vectors.     
An important consideration regarding many acute injuries is that the therapeutic time 
window is short. In those cases, a direct trophic or functional effect of the vector per se could 
extend the therapeutic window, giving time for the transgene to be expressed and mediate 
its own effects. For example, the neuroprotection observed after an acute brain injury using 
the vector termed NLSCt was partially mediated by the transgene overexpressed, but also 
partially mediated by the RGD integrin-interacting motif of the vector itself (Peluffo et al. 
2006; Peluffo et al. 2007). In this experimental setting the direct injection of the vector into the 
lesioned brain area was performed 4 hours after the lesion. The CNS is a tissue that tolerates 
injures very badly due to its high dependence on blood flow and oxygen consumption, and 
its poor regeneration capacity. This determines that the therapeutic window for the 
treatment of acute injuries is very short. Interestingly, even in this experimental paradigm, 
the modular recombinant NLSCt vector overexpressing the anti-oxidant enzyme Cu/Zn 
superoxide dismutase (SOD) could mediate neuroprotection (Peluffo et al. 2006). These 
studies shows the wide possibilities of combining the vectors themselves with active protein 
domains like trophic factors, which will exert rapid direct effects, which in turn may 
increase the therapeutic window or the potency of the effect of the transgene used.  
3. Immunogenicity and inflammation 
The introduction of modular protein vectors into the organism may be accompanied by a 
humoral or cell-mediated immune response against the inserted motifs, which in many cases 
are derived from viral molecules. However, when injected intravenously, the Rabies virus 
glycoprotein (29aa)-Poly-Arg vector (RVG-9R) (see Table 1) did not induce an antibody 
response or an increase in several pro-inflammatory cytokines evaluated (Kumar et al. 2007). In 
another example, when the recombinant 249AL vector (see Table 1) was injected into the 
normal postnatal brain, no changes were observed in glial activation, demyelination, 
recruitment of cytotoxic CD8 lymphocytes, or expression of IL1B. Interestingly, when a very 
similar vector termed NLSCt (see Table 1) was injected into the postnatal brain after an 
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excitotoxic injury, an increase in macrophage/microglia number and in the levels of IL1B and 
Cox2 enzyme were observed in the lesion (Gonzalez et al. 2011). Most interesting, the same set 
of studies discovered that this vector, with or without accomplished control DNA, besides 
inducing an inflammatory response, also induced a decrease in the brain lesion volume and in 
the number of degenerating neurons (Peluffo et al. 2006; Peluffo et al. 2007), an effect that was 
mediated by the prototypic RGD-integrin interacting motif of the vector (Peluffo et al. 2007). 
These data may suggest that the modulation of the inflammation by the vector may be 
beneficial under some circumstances. Another vector termed Tat-PTD-DRBD (see Table 1) did 
not induce interferon (IFN)-A or tumour necrosis factor (TNF)-A responses when incubated 
with primary human peripheral blood mononuclear cells (Eguchi et al. 2009). Thus, the overall 
data suggests that these types of vectors are less immunogenic and pro-inflammatory than 
most viral and other non-viral vectors.  
4. Administration routes and transgene expression 
If these types of vectors are useful for gene therapy applications is still an open question, and 
adequate testing of these vectors in preclinical and actual clinical studies need to be 
performed. In fact, it has been well established that there is no ideal vector for all gene therapy 
applications, being the characteristics of each vector critical for each pathological paradigm. 
The use of modular protein vectors is limited to pathologies accepting an acute treatment, but 
would be ineffective for chronic ones as the transgene expression that they determine is 
normally short lived. The time of transgene expression varies from a few days to more than 
two months, depending on the doses and the method of administration. For instance, 
multifunctional recombinant vectors can induce the in vivo brain expression of a reporter gene 
after direct injection into the bran in a model of acute brain injury, lasting the transgenic 
protein in the brain for 3 days (Peluffo et al. 2003), but another vector was able to determine 
expression in normal brain for two months after intracerebral injection (Navarro-Quiroga et al. 
2002). In the case of other administration routes and pathologies, as for example the 
intravenous administration of these vectors, the time for transgenic protein expression in the 
liver may range from a few days to more that 4 months (Perales et al. 1994). In another study, 
the liver-selective and transient overexpression of the therapeutic protein human coagulation 
factor IX could be achieved using a synthetic modular glycoprotein vector, and secreted factor 
IX into the serum could be detected for 30 days (Ferkol et al. 1993). This same paradigm could 
be used for vaccination, overexpressing transiently the desired immunogenic protein (Chen 
and Huang 2005). Even the use of modular vectors coupled to plasmids producing shRNA 
show potent downregulation of an endogenous gene during 20 days when infused with 
osmotic pumps into the nervous system (Berhanu and Rush 2008). In all this approaches, the 
transient expression of a protein by means of multifunctional vectors would be desirable when 
compared to viral vector inoculation, which present higher risks of oncogenic and 
inflammatory complications, may produce very high levels of transgenic protein, and will 
produce the transgenic protein for life or for extended periods.  
5. Pharmacokinetics and biodistribution  
Various approaches have been undertaken to overcome the interaction of vectors with blood 
components to avoid aggregation as well as embolisms. Moreover for most strategies, the 
phagocytic clearing system of the organism must be eluded. Pharmacokinetic analysis has 
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shown that physicochemical properties of the vectors such as molecular weight, electrical 
charge and immunogenicity (or pre-existing antibodies in the organism) are important 
determinants for the in vivo success of the treatment. In addition, the volume and shape of 
the final vector is also important as it determines if the complex will be internalized into the 
cell and the cell nucleus. P32plasmid DNA is rapidly eliminated from the circulation after 
intra-venous injection in mice (Kawabata et al. 1995), mainly by a scavenger receptor 
mechanism-mediated uptake by hepatic phagocytes (Kawabata et al. 1995; Takakura et al. 
1999). Thus, the in vivo plasmid delivery needs to modify its physicochemical properties by 
condensing carriers. One interesting example is the Mannose-Poly-Lysine vector (Man-PL), 
which was designed to accommodate plasmid DNA for the mannose receptor-mediated 
transfection of liver endothelial cells and Kuppfer phagocytes. After intravenous injection, 
the Man-PL-P32DNA vector disappeared from the plasma with a half-life of 1 minute, being 
80% of the radioactivity recovered from the liver at 10 minutes (mainly in the mannose 
receptor+ target cells) and less than 1% at lungs or kidneys at 1 hour after (Nishikawa et al. 
2000a). This vector had a size of 220nm and a zeta potential of 12,1mV, while the DNA alone 
had a size of 200nm and a zeta potential of -36,4. This type of study clearly shows the 
importance of the condensation of plasmid DNA into small less charged particles. In 
accordance, it has been described that positively charged DNA complexes can activate the 
alternative complement pathway (Plank et al. 1996). The conjugation of vectors with 
hydrophilic polymers has been shown to decrease their interaction with plasmatic proteins 
and blood cells, increasing their half-life in circulation. One of the most used polymers is 
poly (ethylene glycol) (PEG). In an interesting study, Ogris and colleagues compared the 
blood stability of DNA/transferrin/PEI vectors with or without covalently linked PEG. The 
non-PEGylated vectors aggregated in plasma, bound several plasmatic proteins like IgM, 
fibrinogen, fibronectin, and complement C3, and also induced erythrocyte aggregation 
(Ogris et al. 1999). Interestingly, the PEGylated vector showed stable complex size, reduced 
surface charge, reduced binding of plasmatic proteins and erythrocyte aggregation, and 
most important, increased in vivo circulation half-life combined with enhanced transfection 
selectivity towards tumours.  
An interesting vector for improving pharmacokinetics could be the use of natural circulating 
molecules, like the low-density lipoprotein (LDL). In fact it has been shown that LDL can act 
as a vector when mixed with plasmid DNA and injected intravenously, reaching several 
organs including the brain, heart, kidneys and spleen (Guevara et al.). The LDL molecule is 
composed of a highly hydrophobic core, surrounded by a shell of phospholipids and 
unesterified cholesterol, as well as a single copy of Apo B100 protein (Segrest et al. 2001). 
The B100 protein contains several motifs that explain the vector profile of the LDL: i) a motif 
that enable nucleic acid binding, ii) a motif that mediate cellular uptake, and iii) a motif that 
is apparently involved in transferring DNA into the cell nucleus (Guevara et al.). 
Interestingly, low-density particles composed of lipid, Apo B100, RNA, and core protein of 
hepatitis C virus were reported in the plasmas of individuals infected with this virus (Andre 
et al. 2002). This and other studies suggested that virus might utilize the potential of the LDL 
particle to act as a vector as a mechanism for persistent chronic infection. 
6. Preclinical studies 
Many interesting preclinical studies have been performed with modular multifunctional 
protein vectors (see Table 1). The first studies showing in vivo functional effects using 
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modular protein vectors were made by Wu and colleagues. By injecting intravenously the 
asialoorosomucoid glycoprotein-polylysine vector (ASOR-PL, see Table 1), they targeted 
hepatocytes and were able to partially and temporary correct analbuminemia and 
hypercholesterolemia by overexpressing human serum albumin or functional LDL receptor 
respectively (Wilson et al. 1992; Wu et al. 1991; Wu and Wu 1987). In another study, 
neuroprotection from an acute brain injury was achieved after direct intracerebral injection 
of the NLSCt vector overexpressing the antioxidant enzyme Cu/ZnSOD (see Table 1). In 
this experimental setting the overexpression of the therapeutic protein could not only 
induce reduced infarct volume but also functional improvement of the animals (Peluffo et al. 
2006). Here, the vector was injected directly into the lesioned brain by a tightly controlled 
microinjector, using a similar protocol reported for the injection of cells into the human 
Parkinsonian brain (Brundin et al.), or for the intracerebral injection of adeno-associated 
viral vectors  for the treatment of infantile lysosomal storage disease (Worgall et al. 2008). 
Thus, this direct intracerebral injection approach could show some benefits in clinical cases 
of focal traumatic or ischemic injuries, were a delimited area is lesioned and were in some 
cases even a decompressing craniectomy is needed leaving a direct entrance to the brain 
parenchyma. Modular protein vectors have also been used for neuroprotection after acute 
peripheral nerve transection. For example, Barati and colleagues (Barati et al. 2006) delivered 
a polylysine-based polyplex targeting p75NTR positive cells accomplishing the plasmid 
encoding for GDNF after a peripheral nerve transection (see Table 1). They showed an 
almost complete reversal in neuronal death caused by GDNF transgene expression. Though 
this is a very interesting study, the authors performed a subtle pre-lesion to the nerve one 
week before the nerve transection injury to upregulate p75NTR receptor, and thus the same 
experiment should be repeated but under more clinically relevant conditions. In another 
preclinical setting, the intravenous injection (once a day during 3 consecutive days) of the 
RVG-9R vector accomplished to the antiviral siRNA siFvEJ (see Table 1) was able to induce 
80% survival of animals 30 days after their inoculation with a fatal flavivirus (Kumar et al. 
2007). Thought many modular vectors have been shown to mediate over-expression or 
down-regulation of reporter genes, they need to be tested in vivo in clinically relevant 
models for the establishment of their real potential. 
7. Conclusion 
More complex modular protein vectors including all the important domains for efficient 
nucleic acid delivery need to be engineered. They should include domains for DNA 
attachment and condensation, cell attachment and endocytosis, endosomal escape, cytosol 
trafficking towards the nucleus, nuclear import, and DNA release. HNRK (Domingo-Espín et 
al. 2011), fkAbp75-ipr (Berhanu and Rush 2008), and the fusogenic-karyophilic-NT-polyplex 
(Navarro-Quiroga et al. 2002) (see Table 1) are three prototypes of this increasingly complex 
vectors, but additional domains have to be inserted. In addition, an interesting strategy could 
be the exploitation of several domains that have dual functions, like poly-his with DNA 
attachment and endosomal escape properties, like melittin with endosomal escape properties 
and nuclear import potential, or histones with DNA attachment and nuclear import potential. 
Considering the fact that for example several cellular nuclear proteins have several nuclear 
localization domains, the introduction of several domains with the same function in the same 
vector may further increase their efficiency. In fact, dual targeting of cancer cell lines using 
both transferrin and RGD domains showed synergistic effects (Nie et al.). Furthermore, the 
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combination of engineered modular protein vectors with engineered plasmids for long term-
regulated expression in vivo will be essential. For instance, the pEPI DNA vector was the rst 
prototype of episomal vector whose function relies exclusively on chromosomal elements, 
replicating autonomously in low copy numbers in all cells tested (Piechaczek et al. 1999). This 
vector was further engineered to show regulated expression and to be removed from 
transduced cells when transgene expression is no longer needed (Rupprecht et al.). Finally, 
vectors have to be tested in vivo, but evaluating biological effects and not only reporter gene 
expression, and the comparison of different vectors in a same in vivo experimental setting will 
also contribute to the selection of the best prototypes.  
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